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Simple Summary: Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers CML 
treatment is lifelong and many patients experience side effects. For those patients who respond well 
to treatment and achieve deep molecular remission, quality of life is impacted because of continuous 
treatment. In this review, we look at emerging clinical trials which aim to investigate which patients 
can safely stop treatment. Treatment-free remission is the ultimate goal for CML patients, but there 
is still a gap in our knowledge as to why some patients can achieve treatment-free remission, while 
others relapse when treatment is stopped. Here we discuss if there are any prognostic factors that 
can predict the best candidates who qualify for treatment discontinuation, with a view to keeping 
them in remission. 
Abstract: Following the development of tyrosine kinase inhibitors (TKI), the survival of patients 
with chronic myeloid leukaemia (CML) drastically improved. With the introduction of these agents, 
CML is now considered a chronic disease for some patients. Taking into consideration the side ef-
fects, toxicity, and high cost, discontinuing TKI became a goal for patients with chronic phase CML. 
Patients who achieved deep molecular response (DMR) and discontinued TKI, remained in treat-
ment-free remission (TFR). Currently, the data from the published literature demonstrate that 40–
60% of patients achieve TFR, with relapses occurring within the first six months. In addition, almost 
all patients who relapsed regained a molecular response upon retreatment, indicating TKI discon-
tinuation is safe. However, there is still a gap in understanding the mechanisms behind TFR, and 
whether there are prognostic factors that can predict the best candidates who qualify for TKI dis-
continuation with a view to keeping them in TFR. Furthermore, the information about a second TFR 
attempt and the role of gradual de-escalation of TKI before complete cessation is limited. This re-
view highlights the factors predicting success or failure of TFR. In addition, it examines the feasibil-
ity of a second TFR attempt after the failure of the first one, and the current guidelines concerning 
TFR in clinical practice. 
Keywords: chronic myeloid leukemia; chronic phase; tyrosine kinase inhibitor; treatment-free remission; 
TFR deep molecular response; BCR–ABL 
 
1. Introduction 
Chronic myeloid leukaemia (CML) is a heterogeneous haematopoietic disorder and 
is considered the first model in cancer for targeted therapy [1]. Discovery of the Philadel-
phia chromosome [2,3] and the BCR–ABL1 gene [4] and the development of tyrosine ki-
nase inhibitors made a quantum leap in the treatment of CML. The natural history of CML 
makes it a unique disease that arises from leukaemic cells, and then progresses from 
chronic status through an accelerated phase to blast crisis [5]. Moreover, it was reported 
that CML exhibits the oncogenic addiction phenomenon, that is BCR–ABL through its 
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kinase activity is the weakest point of the leukaemic cells [6]. However, recent research 
has illustrated that leukaemic stem cells (LSC) do not depend on the BCR–ABL1 gene [7]. 
BCR–ABL1 became a therapeutic target for leukaemic cells and paved the way for the 
development of tyrosine kinase inhibitors (TKI) that dramatically improved the survival 
of CML patients [8,9]. Furthermore, patients with CML were achieving life expectancy 
near to that of the non-CML population [10–12]. However, now the expectations are rising 
for patients with CML switching from achieving long-term survival to stopping the treat-
ment [13]. In the past, it was reported that a small number of patients on Interferon-Alpha 
could stop the treatment; nowadays, the same concept is being suggested for the patients 
taking TKI [14]. 
In most cases, patients on TKI, achieve deep molecular response (DMR) which im-
proves the survival rates and reduces the chance of disease progression in the future [15–
17]. The ELN defines DMR as undetectable BCR–ABL1 mRNA transcripts in the blood 
using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and/or two 
consecutive high-quality PCR samples with >104 sensitivity [18]. According to interna-
tional scale, deep levels of molecular response is defined as MR4 indicates >4.0-log reduc-
tion (BCR–ABL1IS < 0.01%), MR4.5 indicating >4.5-log reduction (BCR–ABL1IS < 0.0032%), 
and MR5 which indicates >5.0-log reduction (BCR–ABL1IS < 0.001%) [19]. Discontinuing 
TKI, after achieving a DMR will be a novel approach to optimise the treatment and mini-
mising the burden on healthcare systems and patients [20]. This review aims to discuss 
the concept, mechanism, and trials of treatment-free remission (TFR) and reviews poten-
tial predictors of the success or the failure of TFR. Furthermore, it aims to show how far 
the concept of TFR can be clinically applicable. 
2. The Concept of TFR 
Professor John Goldman introduced the concept of the operational cure for patients 
with CML years ago to indicate that patients can have a controlled disease, and a normal 
to near-normal life while continuously taking the TKI [21]. However, TFR takes this con-
cept further by proposing that patients can have a healthy life and controlled disease with-
out the need to continue the treatment after achieving DMR [22]. Although TKI are well-
tolerated and have mild to moderate toxicity, a significant proportion of patients have 
side effects that interfere with their quality of life [23]. Furthermore, newer generations of 
TKI are more powerful and associated with severe adverse events, such as vascular 
events, myocardial infarction, pleural effusion, and pulmonary hypertension [14]. Around 
30% of patients experience side effects from TKI that interfere with their daily activities 
and which on a long-term basis can lead to a decrement in quality of life [24,25]. This is 
quite true for younger patients aged 18–39 as TKI impact their lives more than that of 
older patients [26]. In a multi-centre survey on 329 CML patients, 34% of the responders 
were willing to discontinue TKI, and the main reason was the low quality of life, while 
31% of the participants did not want to stop the TKI because of relapse risk [27] (Figure 
1). Moreover, the survey showed that younger patients, are most likely to attempt TFR 
[27]. Moreover, pregnant women cannot take TKI as this class of medications is contra-
indicated during pregnancy. Although CML is very rare in children, continuously taking 
TKI could affect their growth [1]. Nonetheless, maintaining a good quality of life and ther-
apy cost represent the main two issues of CML patients, and the question to discontinue 
therapy is raised [28,29]. 




Figure 1. Percentage of patients willing to attempt TFR and the reasons given: (a) Percentage of patients willing to attempt 
TFR; (b) The reasons for discontinuing—the main reason that patents cited for wanting to for stopping TKI is the side 
effects; and (c) The reasons for continuing TKI treatment—the main reason patients wanted to continue treatment was 
fear of relapse. Adapted from [27]. 
3. Clinical Trials of TFR 
The first stopping pilot study was conducted in 2004 in France by Professor Mahon 
and colleagues [30]. Clinical trials of TFR are limited with the concept that patients on 
long-term TKI who achieved a durable molecular response can discontinue TKI (Figure 
2). However, most TFR trials have limitations. Firstly, all current trials are non-random-
ised trials except for the HOVON trial, in which patients were randomised into two arms 
after achieving MR4.5 for >2 years. Arm A includes patients who continue Imatinib, and 
arm B patients discontinuing Imatinib [31]. Molecular relapse in arm A was 17% while in 
arm B 67%. Moreover, most of TFR trials are observational studies and in these types of 
studies the risk of selection bias is increased [32]. A survey reported that 56% of patients 
had anxiety and fear of discontinuing TKI [33]. This anxiety and fear affect the selection 
criteria and participation of patients in TFR trials. 
Furthermore, the small population size of the trials is another limitation except for 
the EURO-SKI, which is the largest trial for TFR to date [34]. The EURO-SKI is conducted 
in 11 countries and 61 European centres, including 755 CML patients. Small study samples 
yield false-positive results, and there is a challenge with data interpretation. The absence 
of a generalised and comprehensive definition of undetectable minimal residual disease 
(UMRD) and complete molecular response (CMR) made the comparison between the tri-
als difficult as it depends on the sensitivity qRT-PCR which is not consistent across trials. 
Moreover, eligibility criteria to initiate TFR is different from one study to another. For 
example, molecular response which is a crucial aspect for TFR feasibility, the definition 
and level of response, and trigger for re-initiation of TKI are not standard between the 
trials (Table 1). 
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Type of TKI 
Minimum DMR Du-
ration (y) 
Median Follow up 
(m) 





STIM [35,36] 100 3  IM UMRD ≥ 2  77  2.5 43% at 24 months and 38% at 60 months. Loss of UMRD 
TWISTER [37] 40 3  IM UMRD ≥ 2 43  3 47.1% at 24 months. Loss of UMRD 
ASTIM [38] 80 3 IM MR4 ≥ 2  31  4 64% at 24 months and 61% at 36 months. 
Loss of MMR, 
UMRD 
HOVON [31] 15 2  IM MR
4.5 
>2  36  3 33% at 24 months. Loss of MR
4.5
 
ISAV [39] 108 2  IM UMRD ≥ 1  21.6  NR 48% at 36 months.  Loss of MMR 
KID [40] 90 2  IM MR
4.5 > 2 26.6 3.3 
62.2% at 12 months  
and 58.5% at 24 months. 
Loss of MMR 
EURO-SKI [34] 755 3  IM & NL & DA MR4 ≥ 1 27 6  61% at 6 months and 50% at 24 months. Loss of MRR 
DADI (2015) [41] 63 1  DA DMR ≥ 2  20 3 49% at six months and 48% at 12 months. Loss of MR4 
DADI (2020) [42] 58 3  DA DMR ≥ 2  23.3 2 55% at 6 months. Loss of MR
4
 
ENESTfreedom [43]  190 3  NL MR4.5 ≥ 2 12  NR 51.6 at 48 weeks. Loss of MMR 
Ho-Young Yhim [44]  14 2  IM DMR ≥ 2  23  NR 28.6% at 12 months. Loss of MMR 
GIMEMA [45] 293 7 IM, NL, DA, BO DMR ≥ 3  34 3–4 69% at 12 months and 62% at 34 months. Loss of MMR 
STIM2 [46] 124 3  IM DMR ≥ 2 12 6 61.2% at 12 months. Loss of MMR 
Kieo STIM [47] 40 2  IM DMR ≥ 2 15.5 NR 55.4% at 12 months. Loss of MMR 
Pagnano KB [48] 48 3  IM DMR ≥ 2 NR NR 61% at 20 months. Loss of MMR 
TRAD [49] 67 3  IM MR4.5 ≥ 2 NR NR 64.7% at 6 months. Loss of MMR 
STIM231 [50] 68 3  IM MR
4
 ≥ 2 NR NR 67.6% at 12 months and 65% at 36 months. Loss of MMR 
STOP2G [51] 60 3  NL, DA MR
4.5
 ≥ 2 47 4 
63.3% at 12 months  
and 53.7% at 48 months. 
Loss of MMR 
D-STOP [52] 54 2  DA DMR ≥ 2 16 NR 62.9% at 1 year. Loss of MMR 
DASFREE [53] 84 2  DA MR4.5 ≥ 1 NR 5 48% at 12 months and 46% at 24 months. Loss of MMR 
STATS [54] 78 2  NL MR
4.5
 ≥ 2 35.4 6 
67.9% at 12 months  




DOMEST [55]  99 2  IM MR
4
 ≥ 2 12  NR 
70% at 6 months, 68% at 12 months,  




Abbreviations: IM = Imatinib, DA = Dasatinib, NL = Nilotinib, B = Bosutinib, MR = molecular response, DMR = deep molecular response, TKI = tyrosine kinase inhibitor, MMR = major 
molecular response, TFR- = treatment-free remission, UMRD = undetected minimum residual disease, and NR = not reported. 




Figure 2. TFR concept, patients achieving DMR after long-duration on TKI can attempt for TFR, 
with continuous monitoring, those who relapse will re-initiate the treatment. Abbreviations: TKI = 
tyrosine kinase inhibitor, DMR = deep molecular response, and TFR = treatment-free remission. 
Table 1 demonstrates the characteristics of the trials initiating TFR. These presented 
trials comprise a proportion of data related to TFR that can be of significance in the future. 
What can be observed from Table 1, is the overall TFR rate can be estimated between 40–
70%. Almost all trials require a minimum of two years of treatment with TKI. Moreover, 
the duration of DMR needs to be at least two years. Furthermore, most of the molecular 
relapses occur early within the first six months after TKI discontinuation, potentially sug-
gesting that residual clones are molecularly similar to the original disease. 
4. Mechanisms behind TFR 
To date, mechanisms underlying success or failure of TFR are unknown but research 
suggests that the biology of leukaemic stem cells (LSCs), the microenvironment, and the 
role of the immune system are key [20]. In vitro experiments reported that LSCs are re-
sistant to TKI therapy, and haematopoietic stem cells (CD34+/CD38-cells) do not solely 
depend on BCR–ABL1 for survival [7,56]. With these results, it is important to ask whether 
long-term TKI therapy will eliminate LSCs and is it possible to impose the elimination of 
LSCs as a requirement for TKI cessation? Chomel et al. reported that LSCs are persistent 
in CML patients with UMRD, treated with prolonged IM therapy demonstrated by Ph+ 
culture initiating LSCs [57]. Moreover, the same results were confirmed by Chu et al. 
through BCR–ABL1 expression in CD34+/CD38- cells [58]. These results suggest that LSCs 
remain after long-term TKI therapy, and dynamic models of CML suggest that may would 
take >20 years of IM treatment to eradicate LSCs but this has not been proven [59]. 
Another mechanism explains the role of the immune system in maintaining DMR 
and successful TFR. Before the introduction of TKI, Interferon (IFN) therapy-induced im-
mune activation and targeting stem cells by cytotoxic stem cell survival, enhanced natural 
killer (NK) cells cytotoxicity [60,61]. Three studies further confirmed the role of the im-
mune system in controlling CML after TKI discontinuation by demonstrating low NK 
cells as predictors for molecular relapse [62–64]. On the other hand, those with defective 
immune systems have an increased risk of virus-related carcinomas and other malignan-
cies but not CML [65]. Whether this mechanism occurs in specific cases or in relation to 
other factors, the fundamental role of the immune system needs further evaluation. 
Another mechanism behind TFR concept is the latency that explains the interval in 
which BCR–ABL formation until the diagnosis of CML. This interval is heterogeneous and 
ranges between 2–40 years, following the atomic bombs at Hiroshima and Nagasaki, the 
incidence of leukaemia increased within 2–3 years [66,67]. Alternatively, this could be due 
to stochastic events in which stem cells simply do not divide; however, data showed that 
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this mechanism could occur by chance [68]. Despite these hypotheses, it is essential to 
know that patients with persistent LSCs do not necessarily end with relapses and discov-
ery of biomarkers would allow treatment to be safely discontinued. 
5. Predicting Factors for the Success or the Failure of TFR 
5.1. Duration of TKI 
One of the most consistent factors across all trials that affect TFR is the duration of 
TKI. Most of the trials required a minimum of three years TKI to introduce a successful 
TFR. This factor seems consistent, and the longer the duration, the more chance of TFR 
success. In the STIM trial, the cut-off of Imatinib therapy was 50 months [35]. The esti-
mated survival at 18 months without relapse was 22% for <50 months and 47% for >50 
months TKI. Moreover, the median survival time without relapse was 2.8 and 5.5 months 
for both <50 months and >50 months TKI p = 0.033. A multivariate analysis of the factors 
predicting relapse duration of TKI considered a prognostic factor (hazard ratio 0.421 p = 
0.010) [35]. After long-term follow-up, in the STIM trial, the duration of Imatinib remained 
an independent prognostic factor p = 0.024 [36]. For the EURO-SKI trial, the cut-off level 
of Imatinib was 5.8 years. TFR rate was 41% and 63% for <5.8 years and >5.8 years respec-
tively with an odds ratio of 1.16, p-value = 0.0001[34]. That means an increase by 16% of 
the MMR rate when an additional year of Imatinib is added [34]. 
Furthermore, the results from the TRAD trial were consistent with the previous re-
sults where data cut-off was 8.7 years [49]. The TFR rate for >8.7 years was 79.5% and 
27.9% for those <8.7 years hazard ratio 0.198 p-value < 0.001[49]. Furthermore, Fava et al. 
reported that for each additional year of Dasatinib, there is a 22% decrease in relapse risk 
[45]. Moreover, KID, DOMEST, and DASFREE studies reported that longer TKI duration 
was associated with better TFR rate [40,53,55]. 
5.2. Deep Molecular Response 
The depth or duration of molecular response may be an indicator for the success or 
failure of TFR. Sustained UMRD is defined as the absence of BCR–ABL1 transcript from 
bone marrow or blood sample [57]. In single case studies, it was reported that sustained 
molecular response is related to more disease relapses after TKI cessation [69–71]. Fur-
thermore, many studies reported that the depth of DMR and sustainable UMRD are re-
lated to the success rates of TFR [30,44,46,47]. However, a trial named ‘According to Stop 
Imatinib’ (A-STIM) less strict eligibility criteria were used as patients with occasional low 
levels of BCR–ABL1 transcripts were also included [38]. Furthermore, the re-initiation of 
TKI criteria was the only loss of major molecular response (MMR < 0.1% BCR–ABL1 tran-
script). With a median follow-up time of 31 months, cumulative molecular relapse was 
35% and 36% at 12 and 24 months, respectively [38]. When using the STIM criteria, the 
relapse rate was 54%. Moreover, the relapse-free survival rate was 65% for those with 
stable UMRD and 64% for those with positive low levels of BCR–ABL1 transcript prior to 
IM discontinuation [38]. If there is a deep response, this possibly means that there are 
fewer LSC, and so does a small pool of LSC favour TFR? 
With these findings two points can be derived from this study: (1) low levels of the 
residual disease do not necessarily mean relapse and do not hinder the possibility of suc-
cessful TFR, and (2) introducing TKI discontinuation for a larger group of CML patients 
is possible. The EURO-SKI trial also indicated no differences between the levels of molec-
ular response and their relation to the TFR success rate. However, the long duration of 
DMR seems like a factor to predict the rate of TFR, although this has not been formally 
tested [37,40,50]. In the EURO-SKI trial, longer duration of DMR before TKI discontinua-
tion related to a better chance of TFR [34]. The probability of staying in MMR at six months 
increased by 3% with each year of DMR, odd ratio (1.13 (1.04–1.23) p = 0.0032). The longer 
the duration of DMR, the better the chance of not having a relapse and the possibility of 
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remaining in MMR at six months is 13% [34]. Takahashi et al. reported that there is a sig-
nificant difference between the TFR rates of those with <24 months sustained DMR and 
those with >24 months DMR [72]. Nearly 78% for >24 months and 15% for <24 months p = 
0.0002. However, with the multivariate analysis the duration of DMR did not occur as an 
independent prognostic factor [72]. 
Furthermore, in the TRAD trial cox progression model revealed that there is a strong 
relationship between long duration of MR4 or MR4.5 and relapse-free survival [49]. Never-
theless, the duration of DMR is related to the duration of TKI therapy that means both are 
confounding factors and increase over time (the longer duration of TKI, the longer DMR 
duration). This is why the levels of DMR and early molecular response are related to the 
sensitivity of TKI, and these results were further confirmed by the TWISTER study. [37] 
Around 68% of the relapsed cases occur in the first six months, and TFR rate at two years 
was 47.1% (95% CI, 31.5–62.7%). [37] Moreover, Fava et al. reported that patients in their 
observational study were characterised by the early response within three months, ex-
plaining the comparability of TFR rates between first and second line TKI [45]. 
5.3. BCRABL1 Transcript Type and Detection 
Chronic myeloid leukaemia is driven by the BCR–ABL1 gene which encodes for a 
p210 tyrosine kinase. It is known that there is variability in breakpoint position, the break-
points of chromosome 22 cluster within a small (5.8 kb) region, spanning exons e12–16 
known as the Major Breakpoint Cluster Region (M-BCR). Breakpoint locations almost al-
ways fall between either exons e13 and e14 or between e14 and e15. Although the break-
points in the ABL gene are also variable, because of splicing events, the transcribed mRNA 
has either an e13a2 or an e14a2 junction. The e13a2 and e14a2 BCR–ABL1 transcript types 
differ in length by 75 bp (25 amino acids) [73]. Previous reports prior to the introduction 
of imatinib have, in general, not identified an effect of BCR–ABL1 transcript type on clin-
ical outcome [74–80]. We have previously shown that imatinib-treated patients expressing 
the e14a2 transcript type have a higher and more rapid complete cytogenetic response rate 
than e13a2 expressing patients, thought to be due to higher BCR–ABL tyrosine kinase ac-
tivity [81]. The rate of DMR been found to be lower in e13a2 patients [82–86]. In TFR stud-
ies, e13a2 are more likely to have molecular relapse than e14a2 patients. In the UK Destiny 
study, 15% of e13a2 patient relapsed compared to 7% of patients with e14a2 [87]. In a 
retrospective analysis of an Adelaide cohort, patients with e13a2 BCR–ABL1 transcript 
had higher rates of molecular recurrence after TFR attempts, 66% vs. 35% [88]. These data 
suggest that e13a2 patients may need to be monitored more closely when attempting TFR. 
Droplet digital PCR (ddPCR) is a more sensitive method for quantifying BCR–ABL1 
transcript levels. The BCR–ABL1 levels assessed by ddPCR has been found to predict mo-
lecular recurrence when treatment is discontinued [89]. This supports the theory that the 
lower the BCR–ABL1 level is the higher the chances or achieving a durable TFR, this was 
also observed in the UK Destiny study, which is the only study to include patients in MR3 
and MR4 at trial entry [87]. 
5.4. Immunity Effect 
This topic is controversial in relation to predicting the success or failure of TFR. It is 
suggested that the immune system in CML is not totally compromised and TKI helps re-
activation of the immune system [90,91]. Several sub-studies in the first discontinuation 
studies discuss the relation of baseline immune markers as predictive factors for TFR. In 
preliminary results of Immunostim from the STIM revealed that the count of natural killer 
(NK) cells is lower in patients with relapse than those who maintained relapse-free sur-
vival (145/mm3 (67–450) versus 233/mm3 (70–727), p = 0.0146) [92]. However, NK receptor 
expression did not differ between the two groups [92]. This indicates a positive relation-
ship between the NK cells in the peripheral blood and the rate of TFR, contributing to 
CML control. A sub-study to the EURO-SKI trial held by the Nordic CML study group 
(NCMLSG) reported that patients with high rates of mature (CD57+) and cytotoxic (CD16+ 
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and CD57+) NK cells at the time of TKI discontinuation have higher possibility of success-
ful TFR [93] and this suggests the importance of the surveillance of baseline immune 
markers before TKI discontinuation. It is thought that higher levels of NK cells may be 
capable of both directly killing the LSC and potentiating adaptive immune responses, thus 
maintaining remission after treatment discontinuation. 
In the D-STOP trial, Dasatinib consolidation for two years revealed an increased rate 
of NK cells (CD3−CD56+) in patients who relapsed before Dasatinib cessation [52]. On the 
other hand, in the DADI (2015) trial, after one year of consolidation of Dasatinib, patients 
with increased counts of NK cells (CD3−CD56+ and CD16+/CD56+) and NK cell large gran-
ular lymphocyte (CD56+CD57+) numbers associated with a higher possibility of achieving 
successful TFR [41]. Furthermore, the DADI trial (2020) reported that low CD4 cell count 
prior to Dasatinib cessation is associated with successful TFR [42]. These different results 
can be due to different immune subsets that are introduced by different TKI regimen. For 
instance, in the DADI trial Dasatinib consolidation was used for one year, however in 
EURO-SKI and Immunostim, Imatinib was used. One of the possibilities discussed is the 
presence of Regulatory T (TReg) cells that help the tumour cells to invade the immune 
system and induces relapse in these group of patients. However, studies did not report 
any significant difference in Treg cell counts between patients relapsed and those who did 
not [92,94]. Yoshida et al. reported that Dasatinib inhibits Treg cells, and this is crucial for 
NK differentiation and to achieve DMR [95]. The normalisation of immune defects in pa-
tients with CML is believed to be due to the elimination of leukaemic cells when achieving 
DMR, rather than immune recovery affecting the molecular response [96]. 
5.5. TKI Resistance 
In the STOP 2G-TKI study, 65% of the patients had a previous suboptimal response 
to Imatinib and 21.7% had resistance. The cumulative risk of relapse at 48 months for those 
with prior intolerance of resistance was 76.92% (CI95%, 57.11–100, p = 0.0023) and TFR 
rate was 23.08% [51]. In the DADI (2015) trial patients who switched to Dasatinib due to 
Imatinib resistance had only 7.7% TFR rate at 12 months [41], suggesting that patients with 
previous TKI resistance had higher rates of TFR failure and should not be included in TKI 
discontinuation trials. 
5.6. Prognostic Scoring—Sokal, ELTS, and Eutos Score 
The Sokal score is the first risk-adjusted score that classified CML patients into low-, 
intermediate-, and high-risk patients at diagnosis before initiating the treatment [97]. The 
score measures the percentage of blast cells, platelets, spleen size, and the patient’s age 
[98]. Studies reported that patients with a low-risk Sokal score have better progression-
free survival (PFS) and overall survival (OS) [99,100]. In the STIM trial patients with low 
Sokal score had a better probability of maintaining a DMR at 12 months than those with 
high risk (p = 0.008) and reported the Sokal score as a prognostic factor for molecular re-
lapse (hazard ratio 2.012, (1.252–3.234) p = 0.004) [35]. In the longer follow-up of STIM trial, 
the Sokal score remained an independent prognostic factor p = 0.024 [36]. Similar results 
were reported in the TWISTER study [37] and in the Korean survey of 14 CML patients 
[44]. However, in the TWISTER study, most patients with a low Sokal score were in the 
Interferon–Imatinib cohort, which could be a confounding factor. As a low Sokal score is 
associated with high TFR rate, multivariate analyses of factors affecting TFR showed the 
Sokal score an independent prognostic factor [45,55]. New prognostic scoring systems 
such as the European Treatment and Outcome Study for CML (EUTOS) may be a better 
scoring system to classify CML patients [101,102]. The EUTOS scoring system is estab-
lished by the ELN, by analysing data from 2060 CML patients, who were treated using 
imatinib. Patients were divided into high risk and low risk groups stratified by their abil-
ity to achieve complete cytogenic response (CCyR) in 18 months and PFS [103]. More re-
cently, the EUTOS long-term survival score (ELTS) has been developed to look at the risk 
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of disease progression to the advanced phase [104]. In terms of TFR, ELTS score had a 
weak trend in predicting successful TFR [89]. 
5.7. Age 
Most TFR trials reported no relationship between age at diagnosis and risk of relapse. 
However, an Italian observational study of TKI discontinuation reported age as a statisti-
cally significant variable that affects the rate of TFR. Younger patients are at higher risk of 
relapse than older patients (HR = 0.84 [95%CI 0.73–0.97] p = 0.02) [45]. The same results 
were confirmed by ISAV study with approximately the same age at diagnosis (49 years), 
patients <45 years are more susceptible to experience a relapse than those >45 years p =< 
0.0001 [105]. However, in the DASFREE trial age >65 might help to predict which patients 
are more likely to remain in TFR [39]. Younger patients of CML usually have more ag-
gressive disease, with high blast cell count and splenomegaly [106]. Moreover, younger 
patients have lower cytogenetic and molecular response rates in comparison to older pa-
tients [106]. Understanding these differences and the causes behind them would be help-
ful to enhance the outcomes further. These results suggest that older patients are more 
favourable to achieve successful TFR. These differences could be attributed to the differ-
ences in disease biology, more specifically LSC biology at different ages. HSC lose func-
tion with age [107,108]. Could this be that aged LSC are also less functional and less likely 
to drive relapse? 
5.8. Prior Interferon-Alpha (IFN-a) Therapy 
Only a few trials concluded the significance of the prior IFN-a therapy in relation to 
high TFR rate. In Japan, a retrospective study revealed that patients with previous IFN 
treatment are less likely to relapse within 12 months of TKI discontinuation, with the rate 
of TFR being 76% in patients with prior IFN therapy in comparison to only 23% in those 
with no IFN treatment [72]. Furthermore, IFN therapy was an independent predictor for 
molecular relapse within 12 months (OR 0.0419 (95%CI 0.0044–0.4035) p = 0.0060) [72]. 
Moreover, in the TWISTER study, patients in the IFN-Imatinib cohort had a better TFR 
rate 52% vs. 34% for those only in Imatinib cohort, and longer IFN duration associated 
with higher TFR rates p = 0.05. [37] In the A-STIM study, there was a lower rate of MMR 
loss in patients with previous IFN therapy. However, this trend was not significant and 
could not be analysed as an independent prognostic factor [38]. 
The increased rates of TFR in previously treated patients with IFN could be attributed 
to the selection bias (selecting patients with longer duration of treatment) and low biological 
risk in this cohort of patients [109]. Although the exact mechanism of action of IFN is not 
precisely clear, one of the proposed ways is the effect of IFN on the activation of immune 
effector cells and haematopoietic stem cells [110,111]. This opens up again the role of the 
immune system in maintaining TFR and the importance of immunosurveillance. Although 
a different entity, it is worth of mentioning that Burchert et al. reported that maintenance 
with IFN after TKI cessation improved the molecular response attributing this improvement 
to the activation of a proteinase-3-specific cytotoxic T Lymphocytes [112]. 
5.9. Re-Initiating TKI and Second Attempt TFR 
Molecular relapse was the criteria to re-initiate TKI. However, the measurement of 
these criteria differs among the trials of TKI discontinuation. In STIM molecular relapse 
was defined as positive BCR–ABL1 transcript in qRT-PCR at two successive assessments 
with a ratio of BCR–ABL1 to ABL 10−5 or more [35]. The TWISTER study had a different 
definition, which is a single loss of MMR (>0.1% BCR–ABL1IS) or two consecutive samples 
at any value. [37] However, the A-STIM study changed the concept and defined molecular 
relapse as loss of MMR at any time which is a less stringent criteria [38]. Loss of MMR 
then was used by the EURO-SKI and other studies as a trigger for starting TKI again. 
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As demonstrated in almost all studies discontinuing TKI, patients who relapsed were 
still sensitive to TKI treatment. Although molecular triggers for re-initiating treatment 
differ among the studies, the vast majority of patients regained molecular response within 
six months. It is thought that relapse has the same disease kinetics as the original disease, 
this is because the LSC population is preserved and drives the disease upon relapse. The 
only case that progressed to a blast crisis after re-initiating TKI and gaining MMR for the 
second time was reported by the A-STIM study [38]. Thus, in this case, progression cannot 
be attributed to TKI cessation or related to TFR period, and these cases are called ‘sudden 
blast crisis’ [113,114]. Moreover, another case of nilotinib-resistant F359V BCR–ABL1 ki-
nase domain mutation was detected with loss of MMR in the ENESTfreedom trial. How-
ever, it could not be explained whether the case pre-existed TKI cessation or emerged 
during the TFR period [43]. 
The appropriate time to re-introduce TKI after molecular relapse is another critical is-
sue that needs further follow-up. As recommended by the ELN group, re-initiation of TKI 
should be within less than one month of molecular relapse and followed-up every three 
months after regaining MMR and DMR [115]. Women who are of childbearing age should 
be tested for pregnancy before re-starting the TKI [116]. In cases of patients not responding 
to the re-introduction of TKI, the regimen should be changed to a more potent one. 
Few data are published on a second attempt to discontinue TKI (TFR2) after relapse 
from the first attempt. In the RE-STIM trial, 70 patients attempted a second TFR after re-
lapsing from the first one. All patients in this trial achieved MR4.5 for >2 years. TFR2 rates 
were 48%, 42%, and 35% at 12, 24, and 36 months, respectively. Moreover, no cases pro-
gressed to accelerated phase or blast crisis. The only predictor for a TFR2 was the time to 
molecular relapse in the first TKI discontinuation. Patients who remained DMR within 
the first three months of the first TKI discontinuation had a rate of TFR2 of 72% at 24 
months, while those who relapsed in <3 months the rate of TFR2 was 36% [117]. 
The TRAD study also assessed the feasibility of TFR2 in patients who failed the first 
one. Results show that after treatment with Dasatinib and achieving MR4.5 for more than 
one year, the TFR2 rate was 21.5 ± 8.5% at six months [118]. Again, time to relapse of the 
first attempt was a strong determinant of TFR2 success. The rate of TFR2 at six months 
was 30% in patients relapsing within 3–6 months in the first attempt in comparison to only 
9% for those who relapsed in <3 months [118]. 
Moreover, the TRAD study reported that patients who lost MMR at the first attempt 
had a faster molecular relapse after Dasatinib cessation compared to patients who lost 
MR4[118]. In addition, patients with 5.5 log reduction or deeper in BCR–ABL1 transcript had 
better TFR2 rate at six months (28.7%) versus 0% in patients with 4.5–5.4 log reduction p = 
0.017 [118]. According to these results, a second TFR is feasible in patients who relapsed 
after the first one, and the duration of the first TFR is a very significant factor. Nevertheless, 
the above data suggests that to initiate TFR2, strict criteria should be applied. 
5.10. Abrupt Discontinuation versus Gradual Discontinuation 
It is reported that reducing the dosage of TKI in patients with deep molecular remis-
sion is safe [119], and it will not affect the long-term efficacy of TKI [120]. However, most 
of the TFR studies attempt to abrupt discontinuation of TKI. The British study of the De-
Escalation and Stopping Treatment with Imatinib, Nilotinib, or Sprycel (Destiny) carried 
out a gradual decrease of the TKI to half of the dose for 12 months before discontinuing 
for 24 months. Patients with deep molecular response MR4 and patients with stable MMR 
were included in this study [121]. 
Results of this trial are quite exciting, at 36 months recurrence-free survival was 72% 
for MR4 group and 36% for MMR group [121]. Patients reported better overall symptoms 
and no cases of disease progression were recorded. The results of the Destiny trial are 
significant as the rate of TFR at three years is very high reaching up to 70% (all other trials 
reported TFR rate between 40–60%) and including patients with durable MMR is also an 
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essential step as these group of patients are scarcely included in trials. However, the mech-
anism behind the benefit of de-escalation is still not precise, and more investigations are 
needed for patients with MMR achieving TFR. 
6. Guidelines and Clinical Practice 
There is a difference among published TFR studies in terms of inclusion criteria stop-
ping and re-initiation of the treatment. Nonetheless, a few recommendations have been 
put together by experts, the ESMO guidelines, the NCCN, and the French chronic myeloid 
leukaemia study group (FCMLSG). Table 2 demonstrates some of the guidelines. Such 
practice should only be carried out in highly specialised centres where standardised mo-
lecular testing is conducted as recommended by ESMO [122]. Moreover, the NCCN group 
recommended that ceasing TKI outside clinical trials should only be performed if all cri-
teria are met [123]. These guidelines have been recently reviewed by Professor Clark, a 
leading expert on treatment discontinuation [124]. 
Table 2. Guidelines for TKI discontinuation in clinical practice. 
Criteria FCMLSG [125] NCCN ESMO [122] 
Age  >18 >18 >18 
Phase  CP only CP only CP only 
Sokal score not defined  Not defined  Not a high score 
BCR–ABL1 transcript 
e13a2, e14a2, or 
e13a2 + e14a2 
Quantifiable typical transcript e13a2, e14a2  
TKI duration (years) >5 >3 >5 
DMR type  MR4.5 MR4 MR4.5 
DMR duration (years) >2 >2 >2 
Re-treatment Loss of MMR Loss of MMR or < MR4 Not defined 
Prior history 
No HSCT, no progression, no resistance, 
suboptimal response  
No prior history of progression 
or treatment resistance  
Optimal response 
Abbreviations: CP = chronic phase, TKI = tyrosine kinase inhibitor, DMR = deep molecular response, MMR = major mo-
lecular response, MR = molecular response HSCT = haematopoietic stem cell transplant, FCMLSG= French chronic mye-
loid leukaemia study group, ESMO = European society for medical oncology, and NCCN = national comprehensive cancer 
network. 
It is important to know that when considering any patient for TFR attempt, they 
should be well-educated about the procedure, motivated, fully committed, and not pres-
sured to stop TKI. It was reported in a survey that approximately 10% of patients discon-
tinue TKI due to family pressure [27]. Moreover, the patient should be in the chronic phase 
taking TKI for an extended period, without any recorded resistance or suboptimal re-
sponse. DMR should be achieved for at least two years, with no disease progression to 
blast crisis [14,102,103]. 
Furthermore, physicians should inform the patients about the effects of withdrawing 
TKI an entity known as TKI withdrawal syndrome. This syndrome usually appears as 
musculoskeletal pain, and studies reported that <30% of patients discontinuing TKI expe-
rience pain that may remain for months after withdrawing TKI [126,127]. In the KID study, 
TKI withdrawal syndrome has been related to a better chance to achieve TFR [40]. This 
can cause anxiety; patients should be reassured that this can be treated with either para-
cetamol or non-steroidal anti-inflammatory medications. 
One of the significant obstacles that prevent the establishment of TFR outside the 
clinical trials is the need for frequent monitoring. In the first few months of stopping TKI, 
patients will need frequent molecular monitoring [128]. The ESMO guidelines recom-
mend monthly monitoring in the first six months after TKI discontinuation and three 
months later on [122]. The NCCN guidelines recommend monthly monitoring in the first 
year, then every six weeks in the second year, and every 12 weeks after that [123]. These 
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recommendations are stringent, this is why Ross and Hughes proposed monthly moni-
toring in the first six months, and thereafter every second month [129]. For this purpose, 
a sensitive qRT-PCR is needed with rapid results, and it is important to have standardised 
detection limits of qRT-PCR reporting and high-quality tests [22]. Recently, digital PCR 
(dPCR) has been used to detect BCR–ABL1 mRNA in clinical trials of TFR, and is a pre-
dictor for molecular relapse [40,105]. In the ISAV study, the rates of relapse were higher 
in the dPCR positive group compared to the dPCR negative group [37]. While in KID 
study, negative dPCR at screening was a predictive factor for sustainable MMR [38]. 
Moreover, in a study involving 142 CML patients who discontinued TKI, dPCR improved 
the detection of stable DMR, resulting in better selection of candidates for TFR[130]. Fur-
thermore, Bernardi et al. used dPCR to monitor DMR and assess its value in predicting 
sustained TFR. As the cut-off value for BCR–ABL1 copies/mL was 0.468 by dPCR patients, 
TFR sustainability was higher in patients with dPCR of less than 0.468, compared to pa-
tients with dPCR greater than 0.468. These results suggest that using dPCR to detect very 
low levels of BCR–ABL1 is beneficial in selecting suitable candidates for a TFR trial [130]. 
Claudiani et al. [131] have developed a predictive scoring tool for patients attempting 
TFR. This includes factors such as the probability of TFR in MR3 (pTFR3) and TFR in MR4 
(pTFR4), duration of MR4, previous TKI resistance, age at diagnosis, and transcript type. 
This could become the new “Sokal score” for modern CML treatment, although further 
validation is required. [131]. 
7. Conclusions 
In conclusion, the currently available data on TFR demonstrate that 40–60% of pa-
tients who discontinue TKI can maintain a successful TFR. Most relapses occur within the 
first six months and all patients were sensitive to TKI and gained a molecular response 
upon treatment re-initiation. The long duration of TKI therapy and maintaining DMR for 
>2 years were associated with better TFR rates. Furthermore, a high Sokal score, young 
age, BCR–ABL1 transcript types and level, and TKI resistance indicated the failure of TFR. 
The predictive score for successful TFR reported by Claudiani et al. may offer reassurance 
to clinicians when considering discontinuing treatment [131]. 
In early stopping TKI studies, disease progression was a concern but very few cases 
of progression have been reported [132,133]. However, it is important to note that the 
ISAV study reported that those patients who remain in TFR have at least one positive PCR 
test and using dPCR they estimate that the leukaemic clone may increase by one log over  
three years; why we do not see continuous growth is unknown and an intriguing scientific 
question for future studies. 
For TFR to become a standardised management goal for CML patients, cure rates 
need to be high. This can be achieved by optimising the treatment through new therapeu-
tic approaches, and a high quality and sensitive PCR testing should be available with 
proper and effective monitoring. Clinical trials combining IFN-a and TKI, such as da-
satinib plus Peg-IFN alpha-2b and Peg-IFN alpha-2a combined with nilotinib, reported 
significant DMR rates and patients maintaining better molecular response, although the 
data on TFR rates are not reported yet. However, it is predicted that this combination may 
show promising improvements on the outcomes of TFR. Furthermore, increased prospec-
tive randomised trials in this field will enable clinicians to address the mechanism behind 
the molecular biology of TFR. In summary, treatment-free remission is a real and an 
achievable option for a significant proportion of CML patients, which is arguably a signif-
icant milestone in the timeline of CML developments. 
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